Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
194M
-
Number of holders
-
149
-
Total 13F shares, excl. options
-
138M
-
Shares change
-
-2.69M
-
Total reported value, excl. options
-
$1.25B
-
Value change
-
-$25.4M
-
Put/Call ratio
-
0.46
-
Number of buys
-
67
-
Number of sells
-
-76
-
Price
-
$9.08
Significant Holders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) as of Q2 2022
195 filings reported holding BBIO - BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share as of Q2 2022.
BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) has 149 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 138M shares
of 194M outstanding shares and own 71.25% of the company stock.
Largest 10 shareholders include Kohlberg Kravis Roberts & Co. L.P. (31.1M shares), VIKING GLOBAL INVESTORS LP (26.6M shares), STATE STREET CORP (11M shares), VANGUARD GROUP INC (9.9M shares), BlackRock Inc. (9.36M shares), Aisling Capital Management LP (6.07M shares), HHLR ADVISORS, LTD. (5.36M shares), AMERICAN INTERNATIONAL GROUP, INC. (3.72M shares), D. E. Shaw & Co., Inc. (2.45M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.97M shares).
This table shows the top 149 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.